All Skin TypesNCT06628258
A Clinical Study to Assess the Safety and Effectiveness of Test Product "Moiz Cleansing Lotion" in Healthy Adult Human Subjects With Varied Skin Types. (Dry, Oily, Sensitive, Mixed, Normal)
A study testing Moiz Cleansing Lotion in people with All Skin Types, run by NovoBliss Research Pvt Ltd at 1 site in India.
Trial summary
This is an exploratory, prospective, open-label, interventional, safety in-use, tolerability and efficacy study of the test product "Moiz Cleansing Lotion" in healthy human subjects. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- All Skin Types
- What is being tested?
- Moiz Cleansing Lotion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteIndia
- Study dates
- 23 Oct 2024to 4 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age: 18 to 65 years (both inclusive) at the time of consent.
- Sex: Healthy male and non-pregnant/non-lactating females (Preferably equal).
- Females of childbearing potential must have a self-reported negative pregnancy test.
- Subject are generally in good health.
- Subject with dry, oily, mixed, sensitive and normal skin at a time of screening. (Dermatological Assessment)
- Subjects forearm must be free of cuts, tattoos, scratches, abrasions, scars, uneven skin tone, sunburn, excessive tan, excessive hair or open wounds on or near the test sites
Show all 12Show fewer
- Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
- If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- Subjects are willing to give written informed consent and are willing to come for regular follow up.
- Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study.
- Subject who have not participated in a similar investigation in the past three months.
- Willing to use test product throughout the study period.
Who cannot join
- History of any dermatological condition of the skin diseases.
- Subject with present condition of allergic response to any cosmetic product.
- Subject having allergic response to the ink.
- Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.
- Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal product.
- Subjects who have applied topical product for at least 4 weeks and any systemic product for at least 3 months, before they participated in the study.
Show all 12Show fewer
- History of alcohol or drug addiction.
- Subjects using other marketed products during the study period.
- Any other condition which could warrant exclusion from the study, as per the dermatologist's/investigator's discretion.
- Pregnant or breastfeeding or planning to become pregnant during the study period.
- History of chronic illness which may influence the cutaneous state.
- Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Exploratory, Prospective, Open-Label, Interventional, Safety In-Use, Tolerability and Efficacy Study of Test Product "Moiz Cleansing Lotion" in Healthy Human Subjects.
This is an exploratory, prospective, open-label, interventional, safety in-use, tolerability and efficacy study of the test product "Moiz Cleansing Lotion" in healthy human subjects.
Read the detailed description
27 subjects with different skin type (dry/ oily/ sensitive/ mixed/) of either gender aged between 18 to 65 years old (both inclusive) at time consent will be enrolled to complete 25 subjects/test product in the study.
The potential subjects will be screened as per the inclusion \& exclusion criteria only after obtaining written informed consent from the subjects. Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be called telephonically by the recruiting department prior to the enrolment visit. Subjects will be told during screening (prior to enrolment) not to wear any facial make-up on the study visit day. The adult female subjects will be instructed to visit the facility as per the below visits-
- Visit 01 (Day 01): Screening, Enrolment, Baseline Evaluation, On Site Product Usage, Post Usage Evaluation.
- Visit 02 (Day 15 +2 Days): Product Usage Period, Evaluations
- Visit 03 (Day 30 +2 Days): Evaluations, End of Study
- Conditions
- All Skin Types
- Being tested
- Moiz Cleansing Lotion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Moiz Cleansing LotionOther
Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.
Frequency: Twice a Day Route of Administration: Topical.
| Study group | Role | What they receive |
|---|---|---|
| Dry, sensitive, oily, mixed, normal skin type | Experimental | Test Product Name: Moiz Cleansing Lotion Product By: Glowderma Lab Private Limited Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.
Frequency: Twice a Day Route of Administration: Topical. Receives: Other: Moiz Cleansing Lotion |
What is being measured
The primary outcome is the main question the study is designed to answer.
change in L*, a*, b* value by using Skin Colorimeter
To evaluate the effectiveness of the test product in terms of change in L*, a*, b*
Measured: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in skin impurities using Visiopor® PP34N
To evaluate the effectiveness of the test product in terms of change in skin impurities
Measured: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
Secondary outcomes (15)
change in skin hydration using Corneometer CM 825
To evaluate the effectiveness of the test product in terms of change in skin hydration
Measured: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in skin barrier function using TEWAMeter
To evaluate the effectiveness of the test product in terms of change in skin barrier function
Measured: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in overall dry skin score by dermatological evaluations
To evaluate the effectiveness of the test product in terms of change in overall dry skin score where, 0: means absent and 4 means: Dominated by large scales, advanced roughness, redness present, eczematous changes and cracks
Measured: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in PGA score by dermatological evaluations
To evaluate the effectiveness of the test product in terms of change in PGA score where 0 means: No appearance and 8 means: Severe
Measured: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in product perception questionnaire
- To evaluate the effectiveness of the test product in terms of change in product perception questionnaire where 0 means: Dislike extremely and 9 means liked extremly
Measured: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of scaliness
To evaluate the effectiveness of the test product in terms of change in scaliness where 0 means: Absent and 4 means: Extreme
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of roughness
To evaluate the effectiveness of the test product in terms of change in roughness where 0 means: Absent and 4 means: Extreme
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of redness
To evaluate the effectiveness of the test product in terms of change in redness where 0 means: Absent and 4 means: Extreme
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of itchiness
To evaluate the effectiveness of the test product in terms of change in itchiness where 0 means: None and 4 means: Severe
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of dryness
To evaluate the effectiveness of the test product in terms of change in dryness where 0 means: No Skin Dryness and 4 means: Extreme Xerosis
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of smoothness
To evaluate the effectiveness of the test product in terms of change in smoothness where 0 means: Very rough and 4 means: Very smooth
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in skin irritation
Safety of test product will be evaluated in terms of change in skin irritation by dermatological assessment
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in dryness
Safety of test product will be evaluated in terms of change in dryness by dermatological assessment
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in breakouts
Safety of test product will be evaluated in terms of change in breakouts by dermatological assessment
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in allergic reactions
Safety of test product will be evaluated in terms of change in allergical reactions by dermatological assessment
Measured: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2024
- Study start23 Oct 2024
- Primary completion4 Dec 2024
- Study completion4 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for All Skin TypesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- NovoBliss Research Pvt Ltd
- Sponsor type
- University, hospital or other
- Collaborators
- Glowderma Lab Private Limited
- Responsible party
- Sponsor
- Investigators
- Dr. Nayan K Patel, Principal investigator, NovoBliss Research Pvt Ltd
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06628258
- Sponsor's protocol ID
- NB240043-GL
- Status last verified
- Feb 2025
- First submitted
- 14 Sep 2024
- Last updated
- 3 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory, Prospective, Open-Label, Interventional, Safety In-Use, Tolerability and Efficacy Study of Test Product "Moiz Cleansing Lotion" in Healthy Human Subjects.
- ClinicalTrials.gov ID
- NCT06628258
- Acronym / sponsor ID
- NB240043-GL
- Conditions
- All Skin Types
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- NovoBliss Research Pvt LtdUniversity, hospital or other
- Collaborators
- Glowderma Lab Private Limited
- Study start
- 23 Oct 2024 (actual)
- Primary completion
- 4 Dec 2024 (actual)
- Study completion
- 4 Dec 2024 (actual)
- First posted
- 4 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an exploratory, prospective, open-label, interventional, safety in-use, tolerability and efficacy study of the test product "Moiz Cleansing Lotion" in healthy human subjects.
Detailed description
27 subjects with different skin type (dry/ oily/ sensitive/ mixed/) of either gender aged between 18 to 65 years old (both inclusive) at time consent will be enrolled to complete 25 subjects/test product in the study.
The potential subjects will be screened as per the inclusion \& exclusion criteria only after obtaining written informed consent from the subjects. Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be called telephonically by the recruiting department prior to the enrolment visit. Subjects will be told during screening (prior to enrolment) not to wear any facial make-up on the study visit day. The adult female subjects will be instructed to visit the facility as per the below visits-
- Visit 01 (Day 01): Screening, Enrolment, Baseline Evaluation, On Site Product Usage, Post Usage Evaluation.
- Visit 02 (Day 15 +2 Days): Product Usage Period, Evaluations
- Visit 03 (Day 30 +2 Days): Evaluations, End of Study
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dry, sensitive, oily, mixed, normal skin type | Experimental | Other: Moiz Cleansing LotionTest Product Name: Moiz Cleansing Lotion Product By: Glowderma Lab Private Limited Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry. Frequency: Twice a Day Route of Administration: Topical. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Age: 18 to 65 years (both inclusive) at the time of consent.
- Sex: Healthy male and non-pregnant/non-lactating females (Preferably equal).
- Females of childbearing potential must have a self-reported negative pregnancy test.
- Subject are generally in good health.
- Subject with dry, oily, mixed, sensitive and normal skin at a time of screening. (Dermatological Assessment)
Key exclusion criteria (12 listed)
- History of any dermatological condition of the skin diseases.
- Subject with present condition of allergic response to any cosmetic product.
- Subject having allergic response to the ink.
- Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.
- Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal product.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Moiz Cleansing LotionMode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry. Frequency: Twice a Day Route of Administration: Topical. | Other | Dry, sensitive, oily, mixed, normal skin type |
Primary outcome
change in L*, a*, b* value by using Skin Colorimeter
Time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
To evaluate the effectiveness of the test product in terms of change in L*, a*, b*
change in skin impurities using Visiopor® PP34N
Time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
To evaluate the effectiveness of the test product in terms of change in skin impurities
15 secondary outcomes
change in skin hydration using Corneometer CM 825
Time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in skin barrier function using TEWAMeter
Time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in overall dry skin score by dermatological evaluations
Time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in PGA score by dermatological evaluations
Time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in product perception questionnaire
Time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of scaliness
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of roughness
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of redness
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of itchiness
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of dryness
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in visual and tactile assessment of smoothness
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in skin irritation
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in dryness
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in breakouts
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
change in allergic reactions
Time frame: before usage of test product on Day 01 and after usage of test product at T20 minutes on Day 01, Day 15 and Day 30.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for All Skin Types
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingPhase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Recruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Active, not recruitingPhase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Biphenotypic Leukemia, Acute Leukemia
RecruitingObservational study
Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children
Pediatric ALL, Cardiac Defect
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Nayan K Patel principal investigator
NovoBliss Research Pvt Ltd
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Moiz Cleansing Lotion in people with All Skin Types, run by NovoBliss Research Pvt Ltd at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change in L*, a*, b* value by using Skin Colorimeter (time frame: before usage of the test product on Day 01 and after usage of the test product at T20 minutes on Day 01, Day 15 and Day 30.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2025.